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Escherichia coli O157:H7 was recovered from colon fecal
samples of pigs. Polymerase chain reaction confirmed two
genotypes: isolates harboring the eaeA, stx1, and stx2 genes
and isolates harboring the eaeA,  stx1, and hly933 genes. We
demonstrate that swine in the United States can harbor poten-
tially pathogenic E. coli O157:H7.
D
uring the past two decades, disease caused by Escherichia
coli O157:H7 has been increasing (1). Currently, the
Centers for Disease Control and Prevention estimates that E.
coli O157:H7 causes an average of 500 outbreaks that affect
>73,000 persons and result in >61 deaths each year in the
United States (2). The epidemiology of E. coli O157:H7 has
become an important research topic as manure harboring E.
coli O157:H7 is dispersed, and soil, food, and water are cross-
contaminated with feces containing E. coli O157:H7 (1,3).
Although cattle feces are the most important source of E. coli
O157:H7, the need to evaluate the presence of E. coli O157:H7
in the feces of other animal species has been recognized (1).
The presence of E. coli O157:H7 in swine feces has been
reported in Japan (4), Norway (5), and Chile (6); however, to
date, E. coli O157:H7 has not been reported in swine in the
United States.
The Study
Colon samples were collected at a cooperating swine
slaughter facility from 305 swine carcasses during evisceration.
Two to three inches of distal colon that contained feces at the
first point proximal to the rectum was resected and maintained
on ice for approximately 2 hours before processing (Figure).
Ten grams of feces from each colon was transferred to filter-
lined sterile plastic bags. One hundred milliliters of brilliant
green bile broth (Difco Laboratories, Detroit, MI), prewarmed
to 37°C, was added to each filter stomacher bag containing
feces and incubated at 37°C for 6 h with shaking (150 rpm) (7).
After enrichment, 1.0-mL aliquots were processed by using
Dynabeads anti–E. coli O157 (Dynal Biotech, Oslo, Norway),
according to manufacturer’s instructions with modification.
Bead/sample suspensions were incubated at room temperature
for 30 min with continuous mixing on a Bellco roller drum
(Bellco Glass, Inc., Vineland, NJ) before plating onto sorbitol
MacConkey (SMAC; Difco Laboratories), cefixime/tellurite
(CT; cefixime-tellurite supplement, Dynal Biotech)-SMAC
agars, and rainbow agar O157 (Biolog, Inc., Hayward, CA).
Black colonies from rainbow agar O157 and sorbitol-negative
colonies from CT-SMAC and SMAC agars were tested for the
absence of β-glucuronidase and the ability to ferment lactose
by using E. coli broth containing 4-methylumbelliferyl-β-D-
glucuronide (MUG) (EC medium with MUG; Difco
Laboratories) and MacConkey broth (Difco Laboratories),
respectively. Lactose-positive/MUG-negative isolates were
serotyped by using the RIM E. coli O157:H7 Latex Test
(Remel, Lenexa, KS). Up to 10 E. coli O157 latex agglutina-
tion–positive isolates per colon fecal sample were tested for the
presence of the rfbO157 gene by using polymerase chain reaction
(PCR) (8). Isolates positive for the rfbO157 gene were further
characterized for the presence of genes encoding the H7 flagel-
lar protein (fliCH7), Shiga toxin 1 (stx1), Shiga toxin 2 (stx2),
intimin protein (eaeA), and hemolysin (hly933) (9). We conduct-
ed further analysis using antimicrobial resistance patterns,
pulsed-field gel electrophoresis (PFGE), and ribotyping on all
E. coli O157 PCR–positive isolates containing fliCH7, stx1, stx2,
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Figure. Procedure for isolating Escherichia coli O157 from swine colon
fecal samples.
1Presented in part at the 102nd Annual Meeting of the American Society
for Microbiology, Salt Lake City, Utah, May 2002.eaeA, or hly933. However, for tabulation purposes, each sample
ultimately contributed one isolate. When fliCH7, stx1, stx2, eaeA,
or hly933 was not detected in PCR-confirmed E. coli O157 iso-
lates, further analysis was performed on only one E. coli O157
isolate per colon sample.
E. coli O157 isolates were tested for susceptibility to 17
antimicrobial agents (amikacin, amoxicillin/clavulanic acid,
ampicillin, apramycin, cefoxitin, ceftriaxone, cephalothin,
chloramphenicol, ciprofloxacin, gentamicin, imipenem,
kanamycin, nalidixic acid, streptomycin, sulfamethoxazole,
tetracycline, and trimethoprim/sulfamethoxazole) as described
(10) by using a custom-made semiautomated broth microdilu-
tion assay (Sensititre, Trek Diagnostics, Westlake, OH).
Imipenem was used at concentrations of 0.25–8.0 µg with the
following breakpoints: sensitive (<4) and resistant (16).
For PFGE, DNA was digested with 50 U XbaI (Invitrogen
Corp., Carlsbad, CA) for 4 h at 37°C. PFGE was performed by
using a CHEF Mapper XA system (Bio-Rad, Hercules, CA) at
14°C with pulses ramping from 2.16 s to 63.8 s over 18 h.
PFGE patterns were evaluated visually, and isolates were
assigned to the same pulsotype when exhibiting a difference of
<3 bands from the index isolate. Ribotyping of the E. coli O157
isolates was done by using a RiboPrinter (Qualicon, Inc.,
Wilmington, DE) as described in the user’s manual. Restriction
digests were performed on E. coli O157 isolates by using the
EcoRI enzyme (Qualicon, Inc.).
A total of 305 colon samples were randomly collected on
8 different days over a 6-month period as follows: collection
day 1 (February 16, 2001), n=5; collection day 2 (March 8,
2001), n=20; collection day 3 (March 22, 2001), n=40; collec-
tion day 4 (April 20, 2001), n=40; collection day 5 (May 4,
2001), n=50; collection day 6 (May 16, 2001), n=50; collection
day 7 (June 20, 2001), n=50; and collection day 8 (July 10,
2001), n=50 (Table). Eighteen (5.9%) of the 305 colon samples
had isolates positive for rfbO157. Isolates from 6 of these 18
colon samples also contained fliCH7. Two gene combinations
based on the presence or absence of stx1, stx2, eae, and hly933
were detected in these E. coli O157:H7 PCR-confirmed iso-
lates. The stx1, eaeA, and hly933 virulence pattern was detected
in two isolates (isolates 1 and 2) from two of the five colon
samples collected on February 16, 2001, and the stx1, stx2, and
eaeA virulence pattern was detected in 22 isolates (isolates
6–27) from 4 of the 50 colon samples collected on May 4,
2001. None of the E. coli O157:H7 isolates recovered con-
tained all four of the virulence genes (stx1,  stx2,  eaeA, and
hly933). None of the E. coli O157:non-H7 isolates (isolates 3–5,
28–36) in the present study contained stx1, stx2, eaeA, or hly
genes. Non–Shiga toxin–producing E. coli O157:non-H7 iso-
lates have been previously isolated from the feces of pigs
(11,12). For slaughterhouse visits on March 8, March 22, June
20, and July 10, 2001, E. coli O157 and E. coli O157:H7 were
not recovered from any of the colons sampled.
All E. coli O157:H7 isolates recovered in this study were
sensitive to the antimicrobial agents tested, with the exception
of one isolate (isolate 15) that was resistant to streptomycin.
This isolate was recovered from a colon from which a pan-sen-
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Table. Characterization of Escherichia coli O157:H7 and non-H7 isolates recovered from 305 swine fecal colon samples
a,b 
Collection date 
Swine E.  
coli O157 
isolate no. 
E. coli O157 positive 
colon samples/total colon 
samples collected 
Colon ref. 
no. 
No. of isolates 
recovered from 
sample 
PCR 
characteristics 
E. coli O157 
ribotyping 
PFGE 
type 
Antimicrobial 
resistance pattern
b 
Feb. 16, 2001  1  2/5  1  1  rfbO157, fliCH7, stx1, eae, hly933  H7  1  Pan-sensitive 
  2    2  1  rfbO157, fliCH7, stx1, eae, hly933  H7  1  Pan-sensitive 
Mar. 8, 2001  No isolates  0/20             
Mar. 22, 2001  No isolates  0/40             
Apr. 20, 2001  3  3/40  3  1  rfbO157  Non-H7  3  kan, strept, sulfa, tet 
  4    4  1  rfbO157  Non-H7  3  kan, strept, sulfa, tet 
  5    5  1  rfbO157  Non-H7  3  kan, sulfa, tet 
May 4, 2001  6–11  4/50  6  6  rfbO157, fliCH7, stx1, stx2, eae  H7  2  Pan-sensitive 
  12–16    7  5  rfbO157, fliCH7, stx1, stx2, eae  H7  2  Pan-sensitive, except 
isolate no. 15 resistant 
to strept 
  17–25    8  9  rfbO157, fliCH7, stx1, stx2, eae  H7  2  Pan-sensitive 
  26,27    9  2  rfbO157, fliCH7, stx1, stx2, eae  H7  2  Pan-sensitive 
May 16, 2001  28  9/50  10  1  rfbO157  Non-H7  4  Pan-sensitive 
  29    11  1  rfbO157  Non- H7  4  tet 
  30    12  1  rfbO157  Non-H7  4  tet 
  31    13  1  rfbO157  Non-H7  4  strept, tet 
  32    14  1  rfbO157  Non- H7  4  tet 
  33    15  1  rfbO157  Non-H7  4  tet 
  34    16  1  rfbO157  Non- H7  4  tet 
  35    17  1  rfbO157  Non- H7  4  tet 
  36    18  1  rfbO157  Non-H7  4  tet 
June 20, 2001  No isolates  0/50             
July 10, 2001  No isolates  0/50             
  Total=36  18/305  18           
a Each isolate listed in the following table represents an isolate from an individual colon sample.
 
bFeb., February; Mar., March; Apr., April; ref., reference; PCR, polymerase chain reaction; PFGE, pulsed-field gel electrophoresis; kan, kanamycin; strept, streptomycin; sulfa, 
sulfamethoxazole; tet, tetracycline. sitive E. coli O157:H7 was also recovered. The antimicrobial
sensitivity pattern of the E. coli O157:non-H7 isolates was
more varied than that of the E. coli O157:H7 isolates with five
different susceptibility patterns noted. Only one of the E. coli
O157:non-H7 isolates was pan-sensitive. These data are simi-
lar to previous reports in which antimicrobial resistance among
E. coli O157 non–Shiga toxin–producing isolates was higher
than that of Shiga toxin–producing E. coli O157 isolates (11).
As previously shown, ribotyping did not discriminate
among isolates within the E. coli O157:H7 serotype (13).
Additionally, the E. coli O157:non-H7 isolates were indistin-
guishable from one another. Four PFGE profiles were noted.
The E. coli O157:H7 isolates obtained from colon 1 and colon
2 on February 16, 2001, exhibited the PFGE type 1 pattern,
whereas the E. coli O157:H7 isolates obtained from four colons
on May 4, 2001 exhibited the PFGE type 2 pattern. The E. coli
O157:non-H7 isolates obtained on April 20, 2001, and May 16,
2001, exhibited PFGE patterns 3 and 4, respectively.
Conclusions
Results from this study demonstrate that pigs in the United
States can harbor E. coli O157:H7. The recovery rate of E. coli
O157:H7 from colon fecal samples of pigs reported in this
study was 2.0% (6/305). Previous attempts to isolate E. coli
O157:H7 from swine feces in the United States have been
unsuccessful (12,14). Use of more appropriate methods for
sampling, processing, and culturing swine feces may have
accounted for the ability to recover and isolate E. coli O157:H7
from swine feces in our study. For example, samples were
obtained from the colon, transported on ice, and processed
within 2 h of collection. The absence of antibiotics in our
enrichment step may have also facilitated the recovery of E.
coli O157:H7 from swine feces. Furthermore, although direct
comparisons cannot be made between cattle studies, the recov-
ery rate of Shiga toxin–producing E. coli O157 from cattle
feces has improved over the past 10 years. This is most likely
due to more conducive sampling procedures, culture practices,
and detection methods than an increase in true carriers. The
detection of E. coli O157 in swine feces has previously been
based on the isolation techniques used for the recovery of E.
coli O157 from cattle feces. The difficulty in detecting E. coli
O157 from swine feces may in part be attributable to differ-
ences in the physiologic environment between swine and cattle
feces. More appropriate isolation techniques may still be dis-
covered for detecting E. coli O157 in swine.
Although our recovery rates of E. coli O157:H7 from
swine are similar to recovery rates in Japan (4), we recovered a
genotype in addition to the stx1, stx1, and eaeA genotype: the
stx1, eaeA, and hly933 genotype. In Norway, the recovery rate
(0.1%) of E. coli O157:H7 from pig feces was much lower (5).
Isolates recovered from Norway possessed the stx2 and eaeA
genes only; however, the presence of the hly933 gene was not
determined (5).
The ability to produce one or more Shiga toxins is an
important virulence characteristic of E. coli O157:H7 (1).
However, production of Shiga toxins alone may not be suffi-
cient for E. coli O157:H7 to be pathogenic (1). Other virulence
factors such as the intimin protein (involved in the attachment
of the E. coli O157 to enterocytes), the presence of a plasmid-
encoded hemolysin, or both, are important in the pathophysiol-
ogy of hemorrhagic disease (1). E. coli O157:H7 isolates
recovered in this study possessed either two virulence factors,
eaeA and hly933, in addition to stx1 or one virulence factor, eaeA,
in addition to stx1 and stx2. These isolates can potentially cause
disease and should be considered pathogenic to humans. Since
human E. coli O157:H7 clinical isolates contain the stx1, stx2,
eaeA, and hly933 genes, the human pathogenicity of E. coli
O157:H7 isolates from pigs that lack the hly gene requires fur-
ther study.
The clonal nature of the isolates that were isolated on a
particular day suggests transmission of E. coli O157 between
pigs. Unfortunately, we did not have access to information con-
cerning the source of the pigs from which the samples were col-
lected, the number of pigs slaughtered from a given farm, or the
holding facilities and grouping of the pigs before slaughter.
Therefore, we do not know whether E. coli O157 transmission
between pigs occurred on the farm, in transit, or while the pigs
were in a holding pen at the slaughterhouse.
This study did not permit inferences of E. coli O157:H7
isolation rates with respect to the season, nor can inferences of
E. coli O157:H7 isolation rates be made with respect to swine
or herd prevalence. The relatively low recovery rate of E. coli
O157:H7 from swine feces compared to cattle feces warrants
further study to determine the significance and prevalence of
E. coli O157:H7 in swine and if different enrichment and iso-
lation methods would have an impact on the recovery of E. coli
O157:H7 from swine feces. In addition, future studies should
be conducted to determine the occurrence of E. coli O157 on
swine hides, in swine mouths, and in swine stomachs.
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